We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.81B
1-Year Est. Return 192.15%
This Fund
S&P 500
This Quarter Est. Return
+32.94%
1 Year Est. Return
+192.15%
3 Year Est. Return
+320.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$177M
Cap. Flow
+$101M
Cap. Flow %
15.52%
Top 10 Hldgs %
81.14%
Holding
42
New
5
Increased
20
Reduced
5
Closed
11

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$91.4M
2
NTRA icon
Natera
NTRA
+$24.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$15.9M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$14.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$12.4M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$22.8M
2
BIIB icon
Biogen
BIIB
+$20M
3
UTHR icon
United Therapeutics
UTHR
+$12.9M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.94M
5
FOLD
Amicus Therapeutics
FOLD
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$125M 19.2%
+1,100,000
New +$91.4M
NTRA icon
2
Natera
NTRA
$46.7B
$105M 16.04%
2,603,207
+584,847
+29% +$24.1M
CLDX icon
3
Celldex Therapeutics
CLDX
$3.07B
$71.6M 10.98%
1,605,390
+5,263
+0.3% +$188K
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.78B
$65.2M 10%
2,561,187
+288,272
+13% +$6.72M
PCVX icon
5
Vaxcyte
PCVX
$8.98B
$33.7M 5.17%
703,441
+4,803
+0.7% +$188K
VRDN icon
6
Viridian Therapeutics
VRDN
$2.62B
$30.2M 4.64%
1,034,697
+34,697
+3% +$799K
UTHR icon
7
United Therapeutics
UTHR
$21.4B
$27.8M 4.27%
100,000
-51,009
-34% -$12.9M
VERA icon
8
Vera Therapeutics
VERA
$2.54B
$27.3M 4.18%
1,409,098
-127,083
-8% -$2.3M
CNCE
9
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$25.8M 3.96%
4,420,349
+2,747,308
+164% +$14.4M
GSK icon
10
GSK
GSK
$97.3B
$17.6M 2.7%
501,643
+1,643
+0.3% +$54.7K
BNR
11
Burning Rock Biotech
BNR
$113M
$16.6M 2.55%
739,158
+68,772
+10% +$1.57M
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
$15.5M 2.38%
+300,000
New +$15.9M
AMRN
13
Amarin Corp
AMRN
$301M
$11.7M 1.79%
482,112
+146,105
+43% +$3.51M
LQDA icon
14
Liquidia Corp
LQDA
$6.06B
$11.2M 1.71%
1,752,841
+60,439
+4% +$325K
COGT icon
15
Cogent Biosciences
COGT
$6.12B
$9.18M 1.41%
794,049
-191,106
-19% -$2.37M
TVTX icon
16
Travere Therapeutics
TVTX
$6.23B
$8.79M 1.35%
418,099
+1,370
+0.3% +$29K
WVE icon
17
Wave Life Sciences
WVE
$968M
$8.67M 1.33%
1,238,182
-159,297
-11% -$734K
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.66M 1.33%
+191,158
New +$12.4M
PTGX icon
19
Protagonist Therapeutics
PTGX
$9.44B
$5.68M 0.87%
520,922
+1,710
+0.3% +$14.4K
OLMA icon
20
Olema Pharmaceuticals
OLMA
$961M
$4.96M 0.76%
2,025,234
+625,601
+45% +$1.82M
MCRB icon
21
Seres Therapeutics
MCRB
$55.8M
$4.35M 0.67%
38,833
+192
+0.5% +$25.7K
GOSS icon
22
Gossamer Bio
GOSS
$87.9M
$3.84M 0.59%
1,771,545
+1,385,196
+359% +$11.4M
STRO icon
23
Sutro Biopharma
STRO
$317M
$3.27M 0.5%
+40,454
New +$2.81M
ALLO icon
24
Allogene Therapeutics
ALLO
$643M
$2.49M 0.38%
+396,378
New +$3.67M
PBYI icon
25
Puma Biotechnology
PBYI
$485M
$2.38M 0.36%
561,609
+1,840
+0.3% +$6.35K
1
2

Similar funds

AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return
SFG
Sage Financial Group W. Conshohocken, Pennsylvania $1.81B AUM 22.3% 1-Year Est. Return
GA
Greenspring Advisors Towson, Maryland $1.8B AUM 22.29% 1-Year Est. Return
CCS
Concentric Capital Strategies Stamford, Connecticut $1.8B AUM 51.77% 1-Year Est. Return
PPW
Parcion Private Wealth Bellevue, Washington $1.8B AUM 30.57% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.8B AUM 22.23% 1-Year Est. Return

Kynam Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Kynam Capital Management held 42 positions worth $652M, up 37% from $475M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Kynam Capital Management deployed $101M of net new capital in Q4 2022, opening 5 new positions and adding to 20 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,100,000 shares worth $125M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was United Therapeutics, an estimated $12.9M trimmed.

  • Kynam Capital Management's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,100,000 shares worth $125M.
  • Kynam Capital Management added most to Natera in Q4 2022, an estimated $24.1M increase.
  • Kynam Capital Management's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $12.9M.
  • Kynam Capital Management fully exited Sanofi in Q4 2022, selling an estimated $22.8M.
  • Kynam Capital Management's ten largest holdings make up 81% of its $652M portfolio in Q4 2022.
  • Kynam Capital Management opened 5 new positions and closed 11 in Q4 2022.
  • Kynam Capital Management's portfolio value rose 37% quarter-over-quarter to $652M.

Based on Kynam Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.